<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305043</url>
  </required_header>
  <id_info>
    <org_study_id>VARIANZ</org_study_id>
    <secondary_id>01ZX1310E</secondary_id>
    <nct_id>NCT02305043</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer</brief_title>
  <acronym>VARIANZ</acronym>
  <official_title>Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Adenocarcinoma of the Stomach or Gastroesophageal Junction. A Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify biomarkers predicting response or resistance factors of
      a targeted therapy with trastuzumab in advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of Participants With Objective Response</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR). CR is defined as the disappearance of all target lesions. PR is defined as at least 30% decrease in the sum of the longest dimension of the target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time-to-progression</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The period from study entry until disease progression, death, or date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS is the duration from enrollment to death.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional</intervention_name>
    <description>non-interventional</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffer from histologically proven adenocarcinoma of the stomach or
        gastroesophageal junction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven adenocarcinoma of the stomach or gastroesophageal junction

               -  stage IV

               -  patient receives chemotherapy

               -  signed informed consent

               -  Age &gt; 18 years

        Exclusion Criteria:

          -  Patient can not understand meaning and purpose of the study

          -  patient already received a chemotherapy treatment for advanced disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Lordick, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cancer Center Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivonne Haffner, Dr.</last_name>
    <phone>+49 341 97 12560</phone>
    <email>Ivonne.Haffner@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Cancer Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>November 27, 2014</last_update_submitted>
  <last_update_submitted_qc>November 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Florian Lordick, MD</investigator_full_name>
    <investigator_title>Director University Cancer Center Leipzig</investigator_title>
  </responsible_party>
  <keyword>non-interventional</keyword>
  <keyword>advanced gastric cancer</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

